论文信息 - Mavrilimumab in patients with severe COVID-19 pneumonia and systemic hyperinflammation (MASH-COVID): an investigator initiated, multicentre, double-blind, randomised, placebo-controlled trial - 字舞流文

Mavrilimumab in patients with severe COVID-19 pneumonia and systemic hyperinflammation (MASH-COVID): an investigator initiated, multicentre, double-blind, randomised, placebo-controlled trial

L. Korbee | B. Trapnell | B. V. Van Tassell | A. Abbate | J. Paolini | C. Sheng | A. Duggal | Alison J. Montpetit | S. Dugar | K. Wolski | R. Perrin | D. Sahoo | Tisha Wang | B. Carey | K. Hudock | B. Mandell | Steven Y. Chang | P. Cremer | C. Owen | C. Balog | C. Sewell | A. Bonaventura | G. Wohlford | A. Vecchié | Carla S. McWilliams | Virginia L. Mihalick | J. Mehta | Qiuqing Wang | A. Ho | S. Spencer | Y. Kuramochi | Deborah H. Gladish | S. Gordon | M. Pal | F. Fang | A. Goyanes | H. Wiedemann | Robier A Aguillon Prada | Joan Greer | K. Myers | James Young | D. Nichols | Anna Priday | Prabalini Rajendram | N. Hummel | Deborah Karen Yuki Christina Craig Denise Jill Stephanie A Gladish Myers Kuramochi Sewell Balog Kost | Denise Kosty Sweeny | Jill Kandrac | Jeannie Celiberti | Annie Partisano | J. Coehlo | Any Ladd | Joyce O'Brine | Yub Raj Sedhai | Kristin M. Hudock

[1] M. Landray,et al. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial , 2021, medRxiv.

[2] Christopher M. Horvat,et al. Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19 - Preliminary report , 2021, medRxiv.

[3] G. Criner,et al. Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia , 2020, The New England journal of medicine.

[4] Cameron R. Wolfe,et al. Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19 , 2020, The New England journal of medicine.

[5] Y. Hu,et al. [Asymptomatic infection of COVID-19 and its challenge to epidemic prevention and control]. , 2020, Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi.

[6] Eric A. Meyerowitz,et al. Efficacy of Tocilizumab in Patients Hospitalized with Covid-19 , 2020, The New England journal of medicine.

[7] C. Deutschman,et al. Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes , 2020, The Lancet Respiratory Medicine.

[8] C. Libertin,et al. GM-CSF Neutralization With Lenzilumab in Severe COVID-19 Pneumonia , 2020, Mayo Clinic Proceedings.

[9] E. Audureau,et al. Uncontrolled Innate and Impaired Adaptive Immune Responses in Patients with COVID-19 Acute Respiratory Distress Syndrome , 2020, American journal of respiratory and critical care medicine.

[10] Sharon J Peacock,et al. Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. , 2020, JAMA.

[11] L. Korbee,et al. Targeting GM-CSF in COVID-19 Pneumonia: Rationale and Strategies , 2020, Frontiers in Immunology.

[12] Frederick M. Lang,et al. GM-CSF-based treatments in COVID-19: reconciling opposing therapeutic approaches , 2020, Nature Reviews Immunology.

[13] A. Zangrillo,et al. GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study , 2020, The Lancet Rheumatology.

[14] J. Isaacs,et al. Therapeutic blockade of granulocyte macrophage colony-stimulating factor in COVID-19-associated hyperinflammation: challenges and opportunities , 2020, The Lancet Respiratory Medicine.

[15] L. Dodd,et al. Remdesivir for the Treatment of Covid-19 — Final Report , 2020, The New England journal of medicine.

[16] Thomas Henry,et al. Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions , 2020, Autoimmunity Reviews.

[17] Xiaohu Zheng,et al. Pathogenic T-cells and inflammatory monocytes incite inflammatory storms in severe COVID-19 patients , 2020, National science review.

[18] J. Xiang,et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study , 2020, The Lancet.

[19] P. Conti,et al. Mast cells contribute to coronavirus-induced inflammation: new anti-inflammatory strategy. , 2019, Journal of biological regulators and homeostatic agents.

[20] J. Campbell,et al. Pulmonary pharmacodynamics of an anti-GM-CSFRα antibody enables therapeutic dosing that limits exposure in the lung , 2016, mAbs.

[21] C. Leslie,et al. Influenza induces IL-8 and GM-CSF secretion by human alveolar epithelial cells through HGF/c-Met and TGF-α/EGFR signaling , 2015, American journal of physiology. Lung cellular and molecular physiology.

[22] T. Usui,et al. Pivotal Roles of GM-CSF in Autoimmunity and Inflammation , 2015, Mediators of inflammation.

[23] F. Magrini,et al. Mechanistic Modeling of Antigen Sink Effect for Mavrilimumab Following Intravenous Administration in Patients With Rheumatoid Arthritis , 2012, Journal of clinical pharmacology.

[24] N. Miyasaka,et al. Baseline tumour necrosis factor alpha levels predict the necessity for dose escalation of infliximab therapy in patients with rheumatoid arthritis , 2011, Annals of the rheumatic diseases.

[25] J. Hamilton,et al. GM-CSF in inflammation and autoimmunity. , 2002, Trends in immunology.

[26] W. Lim,et al. Dexamethasone in Hospitalized Patients with Covid-19 , 2021 .